지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제53권 제6호
- 발행연도
- 2019.1
- 수록면
- 347 - 353 (7page)
이용수
초록· 키워드
오류제보하기
Background: Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples. Methods: Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: < 1%, 1%–49%, and ≥ 50%. Results: The intraclass correlation coefficient for TPS was 0.902 ± 0.058. Weighted κ coefficient for 3-step assessment was 0.748 ± 0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type. Conclusions: Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC.
목차
등록된 정보가 없습니다.
참고문헌 (10)
참고문헌 신청
Guan J / 2017 / Programmed death ligand-1(PD-L1)expression in the programmed death receptor-1(PD-1)/PD-L1 blockade : a key player against various cancers / Arch Pathol Lab Med 141:851~861
Reck M / 2016 / Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer / N Engl J Med 375:1823~1833
Langer CJ / 2016 / Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer : a randomised, phase 2 cohort of the open-label KEYNOTE-021 study / Lancet Oncol 17:1497~1508
Gettinger S / 2016 / Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer / J Clin Oncol 34:2980~2987
Roach C / 2016 / Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer / Appl Immunohistochem Mol Morphol 24:392~397
Reck M / 2016 / Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer / N Engl J Med 375:1823~1833
Langer CJ / 2016 / Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer : a randomised, phase 2 cohort of the open-label KEYNOTE-021 study / Lancet Oncol 17:1497~1508
Gettinger S / 2016 / Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer / J Clin Oncol 34:2980~2987
Roach C / 2016 / Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer / Appl Immunohistochem Mol Morphol 24:392~397
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy
Immune Network
2020 .02
-
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Cancer Research and Treatment
2017 .01
-
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Journal of Pathology and Translational Medicine
2019 .01
-
Advantages of robotic PD over laparoscopic PD
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Immune Network
2020 .06
-
PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2019 .12
-
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Journal of Pathology and Translational Medicine
2017 .01
-
Dysphagia Requiring Medical Attention in Parkinson’s Disease: A Korean Population-Based Study
Journal of Korean Medical Science
2023 .04
-
Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists
Journal of Pathology and Translational Medicine
2024 .05
-
Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
Immune Network
2016 .04
-
Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity
Annals of Laboratory Medicine
2024 .09
-
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
Cancer Research and Treatment
2018 .01
-
Clinical Implication of High Sensitivity C-Reactive Protein for the Development of Dementia in Parkinson’s Disease
Dementia and Neurocognitive Disorders(대한치매학회지)
2015 .01
-
Changes in Epidemiological Trends and Rehabilitation Usage in Neurological Diseases in Korea: Parkinson's Disease
뇌신경재활
2021 .01
-
Development of genetically humanized PD-1 mice capable of evaluating preclinical studies of PD-1 immuno-oncology agents
한국실험동물학회 학술발표대회 논문집
2020 .07
-
Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
Endocrinology and Metabolism
2021 .01
-
Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization
Journal of Gynecologic Oncology
2018 .01
-
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
Journal of Pathology and Translational Medicine
2020 .01
-
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Cancer Research and Treatment
2016 .01
-
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Journal of Pathology and Translational Medicine
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0